Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Betamethasone valerate 0.1% scalp application
1304000F0AABDBD
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | 147,614 |
|
Betamethasone valerate 0.1% / Fusidic acid 2% cream
1304000F0AACCCC
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | 116,641 |
|
Betamethasone valerate 0.1% cream
1304000F0AAAAAA
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | 112,273 |
|
Betamethasone valerate 0.025% cream
1304000F0AAABAB
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | 85,914 |
|
Betamethasone valerate 0.1% ointment
1304000F0AABABA
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | 75,746 |
|
Betamethasone valerate 0.025% ointment
1304000F0AABBBB
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | 50,979 |
|
Betamethasone valerate 0.1% / Clioquinol 3% cream
1304000F0AACACA
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | 2,376 |
|
Betamethasone valerate 0.1% / Clioquinol 3% ointment
1304000F0AACDCD
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | 1,977 |
|
Betamethasone valerate 0.1% lotion
1304000F0AABCBC
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | 1,940 |
|
Betamethasone 0.1% foam
1304000F0AABFBF
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | 1,770 |
|
Betamethasone valerate 0.1% / Neomycin 0.5% cream
1304000F0AACBCB
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | 1,227 |
|
Betamethasone valerate 0.1% / Neomycin 0.5% ointment
1304000F0AACECE
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | 729 |
|
Betamethasone valerate 2.25mg medicated plasters
1304000F0AADWDW
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | 458 |
|
Coal tar soln 5% in Betamethasone valerate 0.025% oint
1304000F0AAECEC
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | 97 |
|
Betamethasone valerate 0.1% ointment 25% in Coal tar paste
1304000F0AACSCS
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | 14 |
|
Betamethasone valerate 0.1% oint 10% in White soft paraffin
1304000F0AADBDB
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | 4 |
|
Betamethasone valerate 0.1% oint 50% in Gen Unguentum M crm
1304000F0AAFSFS
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | 4 |
|
Coal tar 5% in Betamethasone valerate 0.025% ointment
1304000F0AAEKEK
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | 4 |
|
Betamethasone valerate 0.1% oint 50% in White soft paraffin
1304000F0AACZCZ
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | 3 |
|
Coal tar 10% in Betamethasone valerate 0.025% ointment
1304000F0AAETET
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | 3 |
|
Coal tar solution 5% in Betamethasone valerate 0.025% cream
1304000F0AAEPEP
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | 3 |
|
Betamethasone valerate 0.1% cream 25% in Coal tar paste
1304000F0AAEQEQ
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | 2 |
|
Betamethasone valerate 0.1% cream 10% in Aqueous cream
1304000F0AACPCP
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | 1 |
|
Betamethasone valerate 0.1% oint 30% in White soft paraffin
1304000F0AADKDK
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | 1 |
|
Betameth val 0.1% crm 25% / Coal tar soln 5% in Unguen M crm
1304000F0AAFKFK
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.